Skip to main content
. 2022 Jun 2;3(2):e146. doi: 10.1002/mco2.146

FIGURE 5.

FIGURE 5

(A) Schematic illustration of MM cell membrane‐coated bortezomib (BTZ) nanoparticles for treatment of multiple myeloma. These biomimetic nanoparticles could enter the bone marrow cavity after intravenous injection, and then target tumor cells through homologous targeting. (B) Bioluminescence images of mice treated with saline (control), blank MPCEC nanoparticles, free BTZ, PCEC@BTZ nanoparticles, and MPCEC@BTZ nanoparticles (Copyright 2022, John Wiley and Sons 222 )